Your browser doesn't support javascript.
Immunological and metabolic characteristics of the Omicron variants infection.
Geng, Jiejie; Yang, Xu; Wang, Kun; Wang, Ke; Chen, Ruo; Chen, Zhi-Nan; Qin, Chuan; Wu, Guizhen; Wang, Youchun; Xu, Ke; Du, Peng; Liu, Jiangning; Chen, Shirui; Zhang, Tao; Sun, Xiuxuan; Guo, Ting; Shi, Ying; Zhang, Zheng; Wei, Ding; Lin, Peng; Wang, Qingyi; Yuan, Jing; Qu, Jiuxin; Zou, Jin; Liu, Yingxia; Lu, Hongzhou; Zhu, Ping; Bian, Huijie; Chen, Liang.
  • Geng J; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Yang X; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Wang K; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Wang K; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Chen R; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Chen ZN; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Qin C; Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100871, China.
  • Wu G; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Preven- tion, Chinese Center for Disease Control and Prevention, Beijing, 100871, China.
  • Wang Y; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, 102629, China.
  • Xu K; MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Preven- tion, Chinese Center for Disease Control and Prevention, Beijing, 100871, China.
  • Du P; Beijing Institute of Biotechnology, Beijing, 100871, China.
  • Liu J; Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100871, China.
  • Chen S; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Zhang T; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Sun X; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Guo T; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Shi Y; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Zhang Z; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Wei D; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Lin P; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
  • Wang Q; School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.
  • Yuan J; The Third People's Hospital of Shenzhen, Shenzhen, 518112, China.
  • Qu J; The Third People's Hospital of Shenzhen, Shenzhen, 518112, China.
  • Zou J; The Third People's Hospital of Shenzhen, Shenzhen, 518112, China.
  • Liu Y; The Third People's Hospital of Shenzhen, Shenzhen, 518112, China. yingxialiu@hotmail.com.
  • Lu H; The Third People's Hospital of Shenzhen, Shenzhen, 518112, China. luhongzhou@fudan.edu.cn.
  • Zhu P; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. zhuping@fmmu.edu.cn.
  • Bian H; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. hjbian@fmmu.edu.cn.
  • Chen L; School of Medicine, Shanghai University, Shanghai, 200444, China. lchen1@shu.edu.cn.
Signal Transduct Target Ther ; 8(1): 42, 2023 Jan 21.
Article in English | MEDLINE | ID: covidwho-2230292
ABSTRACT
The Omicron variants of SARS-CoV-2, primarily authenticated in November 2021 in South Africa, has initiated the 5th wave of global pandemics. Here, we systemically examined immunological and metabolic characteristics of Omicron variants infection. We found Omicron resisted to neutralizing antibody targeting receptor binding domain (RBD) of wildtype SARS-CoV-2. Omicron could hardly be neutralized by sera of Corona Virus Disease 2019 (COVID-19) convalescents infected with the Delta variant. Through mass spectrometry on MHC-bound peptidomes, we found that the spike protein of the Omicron variants could generate additional CD8 + T cell epitopes, compared with Delta. These epitopes could induce robust CD8 + T cell responses. Moreover, we found booster vaccination increased the cross-memory CD8 + T cell responses against Omicron. Metabolic regulome analysis of Omicron-specific T cell showed a metabolic profile that promoted the response of memory T cells. Consistently, a greater fraction of memory CD8 + T cells existed in Omicron stimulated peripheral blood mononuclear cells (PBMCs). In addition, CD147 was also a receptor for the Omicron variants, and CD147 antibody inhibited infection of Omicron. CD147-mediated Omicron infection in a human CD147 transgenic mouse model induced exudative alveolar pneumonia. Taken together, our data suggested that vaccination booster and receptor blocking antibody are two effective strategies against Omicron.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Signal Transduct Target Ther Year: 2023 Document Type: Article Affiliation country: S41392-022-01265-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Signal Transduct Target Ther Year: 2023 Document Type: Article Affiliation country: S41392-022-01265-8